Beddow Capital Management Inc. Increases Position in Organon & Co. (NYSE:OGN)

Beddow Capital Management Inc. boosted its holdings in Organon & Co. (NYSE:OGN) by 2.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 220,900 shares of the company’s stock after acquiring an additional 6,200 shares during the period. Organon & Co. accounts for about 2.0% of Beddow Capital Management Inc.’s investment portfolio, making the stock its 21st largest position. Beddow Capital Management Inc. owned about 0.09% of Organon & Co. worth $4,573,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in OGN. LSV Asset Management grew its stake in Organon & Co. by 47.3% in the 2nd quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock valued at $136,843,000 after acquiring an additional 2,121,940 shares during the last quarter. Norges Bank acquired a new stake in shares of Organon & Co. during the 4th quarter worth about $26,321,000. Wedge Capital Management L L P NC acquired a new stake in shares of Organon & Co. during the 2nd quarter worth about $33,573,000. Allianz Asset Management GmbH boosted its stake in shares of Organon & Co. by 156.5% during the 4th quarter. Allianz Asset Management GmbH now owns 1,900,554 shares of the company’s stock worth $27,406,000 after purchasing an additional 1,159,519 shares during the last quarter. Finally, Kahn Brothers Group Inc. boosted its stake in shares of Organon & Co. by 3,242.4% during the 1st quarter. Kahn Brothers Group Inc. now owns 1,180,204 shares of the company’s stock worth $22,188,000 after purchasing an additional 1,144,894 shares during the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and raised their target price for the stock from $18.00 to $20.00 in a research report on Friday, September 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Organon & Co. has an average rating of “Hold” and a consensus price target of $22.17.

Organon & Co. Trading Down 3.4 %

NYSE OGN opened at $19.49 on Friday. Organon & Co. has a one year low of $10.84 and a one year high of $23.10. The company’s 50 day moving average price is $21.04 and its 200 day moving average price is $20.07. The company has a debt-to-equity ratio of 60.05, a quick ratio of 1.17 and a current ratio of 1.64. The firm has a market capitalization of $5.01 billion, a price-to-earnings ratio of 4.77, a PEG ratio of 0.89 and a beta of 0.85.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.04. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.61 billion. During the same quarter last year, the firm posted $1.31 earnings per share. The business’s quarterly revenue was down .1% on a year-over-year basis. On average, sell-side analysts predict that Organon & Co. will post 4.14 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 5.75%. The ex-dividend date was Friday, August 16th. Organon & Co.’s dividend payout ratio is presently 27.38%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.